Adverum

Adverum Biotechnologies, wholly owned subsidiary of Eli Lilly and Company, is looking for an Associate Director, Scientific & Medical Affairs (Contract) to join our team. This role will be responsible for scientific communication and medical affairs activities including clinical trial, pre-launch an

Adverum Biotechnologies, Inc., wholly owned subsidiary of Eli Lilly and Company, is a mission-driven clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prev

Adverum Biotechnologies, wholly owned subsidiary of Eli Lilly and Company, is looking for a Director, HEOR (Contract) to join our team. The Director, HEOR leads the development and execution of evidence generation strategies across multiple marketed and pipeline assets, indications, and geographies.

Adverum Biotechnologies, Inc., wholly owned subsidiary of Eli Lilly and Company, is a mission-driven clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prev

Adverum Biotechnologies, Inc., wholly owned subsidiary of Eli Lilly and Company, is looking to bring on board a Clinical Scientist/Senior (Contract). This role will support the assigned Clinical Trial Lead with the design and execution of key elements of the Clinical Development Plan (clinical study

Adverum Biotechnologies, Inc., a wholly owned subsidiary of Eli Lilly and Company is a mission-driven clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and pre

Adverum is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal platform, Adv